Connecting Science and Passion
for Breakthrough Therapies
Connecting science and passion to deliver
HyperMabs is a biopharmaceutical company that designs and develops
innovative monoclonal antibody-based therapeutics for life threatening
diseases including COVID-19. We believe in connecting rigorous science with
our innate sense of urgency to rapidly generate breakthrough therapies for
patients in need of a better quality of life. Our highly qualified team of drug
developers and company builders has a track record of advancing complex
biologics from discovery through clinical trials.
Rational design fueled by
years of experience
Our strength is combining superior protein engineering expertise with a deep
understanding of validated biology to rationally engineer novel biotherapeutics
with transformative potential.
Our pipeline product candidates are generated using our leading in-house
in silico design engine for maximum speed and throughput.
A mission to radically transform
We believe in building effective teams that value taking action on the best ideas
to develop new breakthrough therapies at industry leading pace. Our beautiful
20,000 square feet R&D facilities are located in the heart of Montreal, Canada,
and comprise laboratory space for pre-clinical research as well as process
development that bolster our mission to serve patients in need.